Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.
about
Selective estrogen receptor modulators for preventing and treating postmenopausal osteoporosisThe discovery and development of selective estrogen receptor modulators (SERMs) for clinical practiceScreening, diagnosis and treatment of osteoporosis: a brief reviewClinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophyCost-effectiveness of preventative therapies for postmenopausal women with osteopeniaPharmacology and clinical applications of selective estrogen receptor modulators.Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in England.Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis.Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis.Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update.Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia).Effects of tamoxifen versus raloxifene on retinal capillary endothelial cell proliferationTime and dose-dependent effects of Labisia pumila on the bone strength of postmenopausal osteoporosis rat model.Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medicationsHormone replacement therapy and the prevention of postmenopausal osteoporosis.The effects of raloxifene treatment on oxidative status in brain tissues and learning process of ovariectomized ratsWhere are we with postmenopausal hormone therapy in 2005?Osteoporosis prevention and therapy: preserving and building strength through bone quality.Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart diseaseCost-effectiveness of Pharmaceutical Interventions to Prevent Osteoporotic Fractures in Postmenopausal Women with Osteopenia.Cost-effectiveness of bazedoxifene versus raloxifene in the treatment of postmenopausal women in SpainPost-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions.Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene.The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis.SERMs and SERMs with estrogen for postmenopausal osteoporosis.Adverse drug reactions to osteoporosis treatments.Osteoporosis and treatments in Japan: management for preventing subsequent fractures.Melatonin effects on bone: potential use for the prevention and treatment for osteopenia, osteoporosis, and periodontal disease and for use in bone-grafting procedures.Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women.Raloxifene: a selective estrogen-receptor modulator for postmenopausal osteoporosis - a clinical update on efficacy and safety.Raloxifene: a selective estrogen receptor modulator for reducing the risk of invasive breast cancer in postmenopausal women.Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.Recommendations on the management of fragility fracture risk in women younger than 70 years.Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.Effects of raloxifene on the mammary epithelium of female rats in persistent estrus.Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial.Chemoprevention: drug pricing and mortality: the case of tamoxifen.Effects of raloxifene on the urethra of adult castrated female rats.
P2860
Q24200755-B08CDF19-247E-4879-82DE-1164EB1E8CABQ26830744-B2C79691-8901-4CDA-BC4E-D610605A24F5Q26996726-A8E06466-2C57-48BB-905B-BFAAB216C2DBQ28066699-AF478BEA-ADBF-42E3-9DFC-E1211C2F8B5CQ33282322-1E8A04B4-76FE-48C0-8A2D-151C7118D348Q33384192-D7675CA5-1194-44DC-B052-54657310C3E3Q33606022-5C396EDB-2AF3-4B33-AC54-FB9208EB240CQ33613016-5F97582C-6B95-4B97-BDBC-872D762841D0Q34189582-17C6FEA5-9E06-486E-9087-43746F6691A0Q34272056-9252B01F-79EE-43E5-9712-0D0E5AEFE572Q34482507-CF6E0F33-A1B2-4CAA-AA68-0083C3FBB8B8Q35024239-C63638E1-3E66-4763-A0E0-AA6AC93BD29AQ35191452-E7A71539-876A-4654-8615-83EFB2DC9F02Q35740351-CD821CAB-8D99-4E99-A62B-0EB36C652208Q35903603-2A943C84-CFB8-4BF2-AC30-400F64396C09Q36076993-A1AB508C-F026-4F81-8920-A4EE04BE592DQ36350786-2B93E626-24E7-4F54-949B-688A4BD48048Q36565785-3858CF17-FE98-400B-AF98-A5C65B16641DQ36574237-4C7F4EF1-A635-42D3-ACB2-AE8AB57BED16Q36989628-1E777E8F-A889-4AD2-A590-41496AB3B10BQ37006842-6FA83112-A32C-4ACE-9CB9-4B7481439C8DQ37142453-1CCDA97F-74E8-464C-8AC0-50D31B998181Q37192989-4237EEFD-0B00-4776-B4A2-BCC2792C8352Q37357294-D8ACD531-7519-4155-A9ED-1ECB2FE2DB2CQ37698607-932E2FDE-A20B-42BF-B713-2A20A37DA64BQ37743272-2676EA8A-B011-4F94-A016-2C5318E12110Q37973355-1D5A5896-9CD9-4BC5-802B-F0D2024CC412Q38093784-6488215E-E6BD-4033-A298-E353A8686134Q38174174-5267FA4D-64B3-4E91-8FFF-BCB5ACA42979Q38825454-A31A0557-BD26-4CA6-A573-FDCB0933B452Q43267067-94AA0286-6203-496A-93E0-D405313B96F5Q43267077-D0B7A8ED-142C-47D8-B2A2-6BDA646395FCQ43803456-81A0EF04-F7F5-429D-8AEA-4BF4A37DB0E4Q44278781-87622601-1B2B-47E9-97FD-363F4ECDECCFQ45070875-99AA82A4-21B2-4A1E-81BA-1D5E674A2EFDQ45168977-12D54119-C894-4D66-967B-0102FEE4E18EQ45374669-35266010-1191-40E6-A575-5AA0567B001AQ46110515-778748D1-3392-40A7-8CED-F6A69594BEB3Q46203992-8A9A189B-9986-4580-B5C0-5370351894CAQ46259272-D53545A1-62DB-40CD-B0E3-C1A51FEB6743
P2860
Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Safety and adverse effects ass ...... omes of raloxifene evaluation.
@en
Safety and adverse effects ass ...... omes of raloxifene evaluation.
@nl
type
label
Safety and adverse effects ass ...... omes of raloxifene evaluation.
@en
Safety and adverse effects ass ...... omes of raloxifene evaluation.
@nl
prefLabel
Safety and adverse effects ass ...... omes of raloxifene evaluation.
@en
Safety and adverse effects ass ...... omes of raloxifene evaluation.
@nl
P2093
P1476
Safety and adverse effects ass ...... omes of raloxifene evaluation.
@en
P2093
Angelina Ciaccia
Bruce Ettinger
Deborah Grady
Elena Moscarelli
Leo Plouffe
Multiple Outcomes of Raloxifene Evaluation Investigators
Somnath Sarkar
Steven Cummings
P304
P356
10.1097/01.AOG.0000137349.79204.B8
P407
P577
2004-10-01T00:00:00Z